Sandra Robrecht

13PUBLICATIONS
60CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursInnate immunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 20, 2026
Ibrutinib for early-stage CLL: genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

|Mar 30, 2026
Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial.

Moritz Fürstenau, Carsten Utoft Niemann, Sandra Robrecht

|Jan 13, 2026
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.

Othman Al-Sawaf, Benjamin N Locher, Friederike Christen

|Sep 04, 2025
Acalabrutinib treatment for older (aged ≥80 years) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.

Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn

|Aug 27, 2025
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza

|Jan 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.

Moritz Fürstenau, Sandra Robrecht, Christof Schneider

Pageof 3

Frequent Collaborators

9 joint publications

Michael J Hallek

6 joint publications

Moritz Fürstenau

5 joint publications

Florian Simon

5 joint publications

Petra Langerbeins